4//SEC Filing
Rosen Oliver 4
Accession 0000899243-18-024910
CIK 0001654151other
Filed
Sep 19, 8:00 PM ET
Accepted
Sep 20, 4:20 PM ET
Size
25.5 KB
Accession
0000899243-18-024910
Insider Transaction Report
Form 4
Rosen Oliver
Chief Medical Officer
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2017-10-02−36,746→ 0 totalExercise: $1.89Exp: 2025-12-17→ Common Stock (207,614 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2017-10-02+207,614→ 207,614 totalExercise: $1.89Exp: 2025-12-17→ Common Stock (207,614 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2017-10-02−8,166→ 0 totalExercise: $1.89Exp: 2025-12-17→ Common Stock (46,137 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2017-10-02+46,137→ 46,137 totalExercise: $1.89Exp: 2025-12-17→ Common Stock (46,137 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2017-10-02+48,025→ 48,025 totalExercise: $3.95Exp: 2026-09-26→ Common Stock (48,025 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2017-10-02−8,121→ 0 totalExercise: $6.13Exp: 2027-06-03→ Common Stock (45,883 underlying) - Award
Stock Option (Right to Buy)
2018-02-16+68,500→ 68,500 totalExercise: $29.71Exp: 2028-02-15→ Common Stock (68,500 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2017-10-02+45,883→ 45,883 totalExercise: $6.13Exp: 2027-06-03→ Common Stock (45,883 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2017-10-02−8,500→ 0 totalExercise: $3.95Exp: 2026-09-26→ Common Stock (48,025 underlying)
Footnotes (7)
- [F1]Immediately prior to the closing of the Issuer's initial public offering, these options to purchase common stock of Deciphera Pharmaceuticals, LLC were exchanged for options to purchase common stock of the Issuer on a 1 for 5.65 basis pursuant to that certain Reorganization Agreement and Plan of Merger by and among the Issuer, Deciphera Pharmaceuticals, LLC and the other parties named therein, dated September 26, 2017 (the "Merger Agreement"). These transactions were exempt from Section 16(b) in reliance upon Rule 16b-3 and Rule 16b-6(b).
- [F2]This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 16 equal quarterly installments at the end of each quarter following the vesting commencement date of June 6, 2014, subject to continued service through such dates.
- [F3]Represents the total number of options to purchase common stock of the Issuer received upon the exchange of options to purchase common stock of Deciphera Pharmaceuticals, Inc. for options to purchase common stock of the Issuer pursuant to the Merger Agreement.
- [F4]This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 48 equal monthly installments at the end of each month following the vesting commencement date of September 30, 2015, subject to continued service through such dates.
- [F5]This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 48 equal monthly installments at the end of each month following the vesting commencement date of July 1, 2016, subject to continued service through such dates.
- [F6]This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 48 equal monthly installments at the end of each month following the vesting commencement date of May 26, 2017, subject to continued service through such dates.
- [F7]This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option vests in 48 equal monthly installments following the vesting commencement date of January 1, 2018, subject to continued service through such dates.
Documents
Issuer
Deciphera Pharmaceuticals, Inc.
CIK 0001654151
Entity typeother
Related Parties
1- filerCIK 0001714870
Filing Metadata
- Form type
- 4
- Filed
- Sep 19, 8:00 PM ET
- Accepted
- Sep 20, 4:20 PM ET
- Size
- 25.5 KB